UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

c

Date of Report (Date of earliest event reported): May 8, 2024

CARTESIAN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

001-37798 (Commission File Number) 26-1622110 (IRS Employer Identification No.)

Delaware (State or other jurisdiction of incorporation)

> 704 Quince Orchard Road, Gaithersburg, MD 20878 (Address of principal executive offices)(Zip Code)

-

(617) 923-1400 Registrant's telephone number, including area code

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- □ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- □ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock (Par Value \$0.0001)	RNAC	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company D

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On May 8, 2024, Cartesian Therapeutics, Inc. (the "Company") announced its financial results for the quarter ended March 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 7.01. Regulation FD Disclosure.

The Company from time to time presents and/or distributes to the investment community at various industry and other conferences slide presentations to provide updates and summaries of its business. A copy of its current corporate slide presentation is attached to this Current Report on Form 8-K as Exhibit 99.2.

The information in Items 2.02 and 7.01 of this Form 8-K, including Exhibits 99.1 and 99.2 attached hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.2, except as required by law.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

 Exhibit No.
 Exhibit Description

 99.1
 Press Release of Cartesian Therapeutics, Inc. dated May 8,2024

 99.2
 Corporate slide presentation of Cartesian Therapeutics, Inc. dated May 2024

 104
 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CARTESIAN THERAPEUTICS, INC.

Date: May 8, 2024

By:

/s/ Carsten Brunn, Ph.D. Carsten Brunn, Ph.D. President and Chief Executive Officer



Cartesian Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Topline data from Phase 2b trial of Descartes-08, the Company's potential first-in-class mRNA CAR-T cell therapy, in myasthenia arayis on track for mid-2024

On track to dose first patient in Phase 2 trial of Descartes-08 in SLE in 2Q24, as well as Phase 2 basket studies in additional autoimmune indications in 2H24

New headquarters expected to support scale of wholly owned, in-house cGMP manufacturing capabilities for clinical and commercial supply of Company's pipeline of mRNA cell therapy product candidates

Approximately \$104.8M of cash, cash equivalents, and restricted cash as of March 31, 2024, expected to support planned operations into 2H 2026

GAITHERSBURG, MD, May 8, 2024 (GLOBE NEWSWIRE) - Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today reported financial results for the first quarter ended March 31, 2024, and recent corporate updates.

"We continue to make meaningful progress advancing our innovative pipeline of product candidates and remain on track to report topline results from the Phase 2b trial of our lead product candidate, Descartes-08 for MG, in mid-2024," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. "Looking ahead, we also expect to commence dosing in our Phase 2 trial of Descartes-08 in patients with SLE by the end of the second quarter. Descartes-08 is designed with our novel mRNA-engineered CAR-T technology, is not expected to require preconditioning chemotherapy, and is intended to be administered in an outpatient setting. We remain confident Descartes-08 has the potential to expand the reach of cell therapy to patients with autoimmune diseases and serve as the first CAR-T cell therapy for the treatment of autoimmunity."

Dr. Brunn continued, "Additionally, we were excited to announce plans to transition to new corporate headquarters in Frederick, Maryland, that will provide us with the infrastructure to support our next phase of growth. We expect this new facility will allow us to scale our wholly owned, in-house cGMP manufacturing capabilities for late-stage clinical and commercial supply of our mRNA cell therapy product and the stage of growth. candidates, while continuing to maintain control over product quality and production."

Recent Pipeline Progress and Anticipated Milestones

Descartes-08 for Myasthenia Gravis (MG)

- Topline data from randomized Phase 2b trial in patients with MG on track for mid-2024
- Recently granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of MG. Previously disclosed positive, long-term follow-up results from Phase 2a trial. In April 2024, the Company announced that these data will be featured in an oral presentation at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting on May 10, 2024 in Baltimore, Maryland.
- Descartes-08, the Company's lead product candidate, is an autologous anti-B cell maturation antigen (BCMA) mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T).

Descartes-08 for Systemic Lupus Erythematosus (SLE)

- Dosing of first patient in Phase 2 trial of Descartes-08 in patients with SLE expected in second quarter of 2024. The Phase 2 trial is designed to assess the safety and tolerability of outpatient Descartes-08 administration without preconditioning chemotherapy.
- SLE is an incurable autoimmune disease marked by systemic inflammation that affects multiple organ systems and impacts approximately 1.5 million people in the United States.



Descartes-15 for Multiple Myeloma

- Planning for the first-in-human Phase 1 dose escalation trial is underway to assess the safety and tolerability of outpatient Descartes-15 administration in patients with multiple myeloma. Descartes-15 is a next-generation autologous anti-BCMA mRNA CAR-T product candidate designed to have predictable and controllable pharmacokinetics, potentially circumventing preconditioning
- chemotherapy, and avoiding the risk of genomic integration. The Company expects to subsequently assess Descartes-15 in autoimmune indications.

Corporate Updates

Preferred Stock Conversion and Reverse Stock Split Approved at Special Meeting of Stockholders

- In March 2024, Cartesian announced the approval for the conversion of the Company's Series A Non-Voting Convertible Preferred Stock into the Company's common stock and a 1-for-30 reverse stock split of the Company's common stock.
- Following the reverse stock split and the automatic conversion of the Company's Series A Non-Voting Convertible Preferred Stock into common stock, the number of issued and outstanding shares of • the Company's common stock is approximately 17.8 million shares.

- Transitioning Corporate Headquarters to Frederick, Maryland
 In March 2024, the Company <u>announced</u> plans to transition its corporate headquarters to Frederick, Maryland. Following this announcement, Cartesian further expanded the footprint of this facility by approximately 30% through an amended agreement.
- The Company now has approximately 27,000 square feet of state-of-the-art current good manufacturing practice (cGMP) compliant manufacturing and laboratory space, as well as general and administrative office space to support the Company's continued growth. This facility reinforces the development of Cartesian's clinical and preclinical programs through clinical and commercial manufacturing scale capabilities and advanced research and development laboratory space.
- by conducting all manufacturing in-house, Cartesian expects to optimize processes more rapidly and iteratively while directly working to ensure adherence to strict quality standards. The Company believes this facility will facilitate production of potent yet safer, cost-effective mRNA cell therapy product candidates for late-stage clinical and commercial supply.

First Quarter 2024 Financial Results

- Cash, cash equivalents, and restricted cash of approximately \$104.8 million as of March 31, 2024. The Company's cash, cash equivalents and restricted cash as of March 31, 2024 is expected to support planned operations and the development of Cartesian's pipeline into the second half of 2026, including the planned Phase 3 trial of Descartes-08 in MG.
- Research and development expenses were \$9.7 million for the quarter ended March 31, 2024, compared to \$18.6 million for the quarter ended March 31, 2023. The decrease in research and development expenses of \$8.9 million for the quarter ended March 31, 2024 was primarily the result of reductions in expenses incurred for preclinical and clinical programs due to the strategic reprioritization in the Company's clinical pipeline.
- General and administrative expenses were \$9.5 million for the quarter ended March 31, 2024, compared to \$5.7 million for the quarter ended March 31, 2023. The increase in expense of \$3.8 million for the quarter ended March 31, 2024 was primarily due to an increase in professional fees incurred in connection with the Company's merger in November 2023.
- Net loss was \$(56.8) million, or \$(10.50) per share (basic/diluted), for the quarter ended March 31, 2024, compared to net loss of \$(21.7) million, or \$(4.24) per share (basic/diluted), for the quarter ended March 31, 2023.

About Cartesian Therapeutics



Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company's lead asset, Descartes-08, is a potential first-in-class mRNA CAR-T in Phase 2b clinical development for patients with generalized myasthenia gravis. Additional Phase 2 studies are planned in systemic lupus erythematosus under an allowed IND, as well as basket trials in additional autoimmune indications. The Company's clinical-stage pipeline also includes Descartes-15, a next-generation, autologous anti-BCMA mRNA CAR-T. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X, formerly known as Twitter.

Forward Looking Statements

Any statements in this press release about the future expectations, plans and prospects of the Company, including without limitation, statements regarding the Company's expected cash resources and cash runway, the Company's estimated cash on hand, the Company's headquarters relocation, the Company's manufacturing capabilities and ability to supply necessary quantities of its product candidates for clinical trials and potential commercialization, the Company's between the company's technology to enable precision control and optimization of engineered cells for diverse cell therapies leveraging multiple modalities, the potential of Descartes-08 and Descartes-15 and the Company's ther product candidates to treat myasthenia gravis, systemic lupus erythematosus, or any other disease, the anticipated initiation timing of planned clinical trials, the anticipated timing or the outcome of the EDA's review of the Company's regulatory filings, the Company's builty to consummate any expected agreements and licenses and to realize the anticipated benefits thereof, the novelty of treatment paradigms that the Company's sellicity of the Statement scontaining the words "anticipate," "believe," "continue," "could," "estimate," "expect," "hypothesize," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to the Company's technology, potential delays in enrollment of patients, undersinable side effects of the Company's technology, and inhibity and timing of adar from ongoing and future clinical trials, and there results of stucles performed on nesults of stucles performed on human beings based on results of stucles, perturbating, the eability to maintain its existing or future collaborations, license



Cartesian Therapeutics, Inc. and Subsidiaries Consolidated Balance Sheets (Amounts in thousands, except share data and par value)

	м	arch 31, 2024	December 31, 2023
		(Unaudited)	
Assets			
Current assets:			
Cash and cash equivalents	S	103,418 \$	5 76,911
Accounts receivable		2,006	5,870
Unbilled receivables		2,370	2,981
Prepaid expenses and other current assets		3,315	4,967
Total current assets		111,109	90,729
Non-current assets:			
Property and equipment, net		2,402	2,113
Right-of-use asset, net		9,556	10,068
In-process research and development assets		150,600	150,600
Goodwill		48,163	48,163
Long-term restricted cash		1,377	1,377
Investments		2,000	2,000
Total assets	S	325,207 \$	305,050
Liabilities, convertible preferred stock, and stockholders' deficit			
Current habilities:			
Accounts payable	s	2,517 \$	3,150
Accrued expenses and other current liabilities		9,516	15,572
Lease liability		2,229	2,166
Deferred revenue		412	2,311
Warrant liabilities		597	720
Contingent value right liability		21,383	15,983
Forward contract liabilities		-	28,307
Total current liabilities		36,654	68,209
Non-current liabilities:		,	
Lease liability, net of current portion		8,228	8,789
Deferred revenue, net of current portion		_	3,538
Warrant liabilities, net of current portion		4,755	5,674
Contingent value right liability, net of current portion		376,517	342,617
Deferred tax liabilities, net		15,853	15,853
Total liabilities		442,007	444,680
Series A Preferred Stock, \$0,0001 par value; no and 548,375 shares authorized as of March 31, 2024 and December 31, 2023, respectively; no and 435,120.513 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	h	_	296,851
Options for Series A Preferred Stock		-	3,703
Stockholders' deficit:			
Series A Preferred Stock, \$0.0001 par value; 548,375 and no shares authorized as of March 31, 2024 and December 31, 2023, respectively; 534,260.839 and no shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	h	_	_
Preferred stock, \$0.0001 par value; 10,000,000 and 9,451,625 shares authorized as of March 31, 2024 and December 31, 2023, respectively; no shares issued and outstanding as of March 31, 2024 and December 31, 2023		_	_
Common stock, \$0.0001 par value; 350,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 5,515,836 and 5,397,597 shares issued and outstanding as of March 31, 2024 and December 31, 2023; respectively		1	1
Additional paid-in capital		559,275	179,062
Accumulated deficit		(671,471)	(614,647)
Accumulated other comprehensive loss		(4,605)	(4,600)
Total stockholders' deficit		(116,800)	(440,184)
Total liabilities, convertible preferred stock, and stockholders' deficit	S	325,207 \$	305,050



Cartesian Therapeutics, Inc. and Subsidiaries Consolidated Statements of Operations and Comprehensive Income (Loss) (Amounts in thousands, except share and per share data)

		Three Months Ended March 31,	
		2024	2023
		(Unaudit	ted)
Collaboration and license revenue	Ş	5,840	5,938
Operating expenses:			
Research and development		9,738	18,624
General and administrative		9,450	5,695
Total operating expenses		19,188	24,319
Operating loss		(13,348)	(18,381)
Investment income		1,164	1,331
Foreign currency transaction, net		_	19
Interest expense		_	(808)
Change in fair value of warrant liabilities		1,042	(4,079)
Change in fair value of contingent value right liability		(39,300)	_
Change in fair value of forward contract liabilities		(6,890)	_
Other income, net		508	255
Net loss	\$	(56,824)	\$ (21,663)
Other comprehensive (loss) income:			
Foreign currency translation adjustment		(5)	(22)
Unrealized gain (loss) on marketable securities		_	11
Total comprehensive loss	S	(56,829)	\$ (21,674)
Net loss per share:			
Basic and Diluted	S	(10.50)	6 (4.24)
Weighted-average common shares outstanding:	<u> </u>	(10.50)	v (1 .21)
Basic and Diluted		5,414,020	5,111,518



Investor Contact Ron Moldaver ron.moldaver@cartesiantx.com

Media Contact David Rosen Argot Partners cartesian@argotpartners.com



Forward-Looking Statements

Disclosures

For the purposes of this notice, the "presentation" that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Cartesian Therapeutics, Inc. (the "Company") or any person on their behalf, any question-and-answer session that follows such oral presentation, hard copies of this document and any materials distributed at, or in connection with, such oral presentation.

Forward-looking Statements

Any statements in this presentation about the future expectations, plans and prospects of the Company, including without limitation, statements regarding the Company's expected cash resources and cash runway, the Company's estimated cash on hand, conversion of the Company's remaining Series A Non-Voting Convertible Preferred Stock, the Company's in-house manufacturing capabilities, the potential of Rexarders-08. Descartes-15, Descar

2

Cartesian

Clinical-stage company pioneering mRNA cell therapies designed to expand the reach of cell therapy to autoimmunity

- Pipeline of mRNA cell therapies designed to be dosed more reliably and safely in an outpatient setting without lymphodepletion
- Descartes-08: Potential first-in-class mRNA CAR T-cell (CAR-T) demonstrated deep and durable clinical responses in Phase 2a study in patients with myasthenia gravis (MG)
- Wholly-owned GMP manufacturing designed to enable rapid optimization of processes in iterative manner

Cartesian

MULTIPLE ANTICIPATED NEAR-TERM CATALYSTS

DESCARTES-08

- Phase 2b topline data in MG expected mid-2024
- Initiation of Phase 2 study in SLE expected in 1H 2024
- Initiation of studies in additional autoimmune indications expected in 2H 2024

DESCARTES-15

- · Next-generation mRNA CAR-T candidate
- IND cleared, with first-in-human Phase 1 planning activities underway


STRONG CASH RESOURCES

\$104.8M as of March 31, 2024; expected to fund currently planned operations into 2H26


Expected to provide for continued clinical development of Descartes-08 in MG through Phase 3 and multiple additional clinical programs

CAR, Chimeric antigen receptor SLE, Systemic Lupus Erythematos

Experienced management team to lead the mRNA cell therapy company of the future




Cartesian's mRNA approach is designed to expand the reach of potent cell therapy products to address potential autoimmune indications



Wholly-owned pipeline targets autoimmune disease





Cartesian

Descartes-08 is designed for dual action, precisely targeting two key BCMA+ cell populations involved in a spectrum of autoimmune diseases

Descartes-08 is designed to target BCMA, a surface antigen expressed on *plasma* cells/plasmablasts and plasmacytoid dendritic cells

PLASMA CELLS (PCs) AND PLASMABLASTS


- PCs, plasmablasts and proliferating B cells targeted by Descartes-08 represent a tiny fraction of B cells
- These cells are entirely responsible for secreting pathogenic autoantibodies
- During autoimmunity, autoantibodies attack host tissue and drive inflammation

PLASMACYTOID DENDRITIC CELLS (pDCs)

- pDCs, which Descartes-08 is designed to target, are a rare subset of antigen-presenting cells
- These cells secrete high levels of cytokines (i.e., type I interferons) that cause
 inflammation and tissue damage during many human autoimmune diseases
- pDCs are increased in patients with autoimmunity (e.g., SLE) and interfere with optimal treatment

Several autoimmune disease segments involve pathogenic contributions from *both PCs/plasmablasts* and *pDCs*, including rheumatology, nephrology, neurology, and others Selectively deleting PCs/plasmablasts and pDCs, if successful, may create a differentiated cell therapy platform


Cartesian BCMA: B cell maturation antigen; SLE: systemic lupus erythematosus



Initial indication for Descartes-08: Myasthenia gravis


- Affects over 120,000 patients in US and EU
- Characterized by debilitating weakness: limbs, respiratory, ocular, facial muscles
- Standard of care includes chronic use of immunosuppressants, which are often toxic:
 - Progressive disease that is fatal in 1/3 of patients without immunosuppressants
- Newer agents include complement inhibitors and anti-FcRn mAbs, which must be administered chronically to maintain responses
- Pathogenesis is similar across many autoimmune diseases; involves attack on self by both T cells and B/plasma cells

Cartesian



9

Phase 2 study of Descartes-08 in MG (NCT04146051)



	Mean age, years (SD)	52 (18)	Previous myasthenia gravis			
Phase 1/2a	Female	10 (71%)	therapies (standard of care)			
	Male	4 (29%)	Pyridostigmine	14 (100%)		
study population	Mean weight, kg (SD)	84 (21)	Prednisone	14 (100%)		
comprises patients	Mean BMI, kg/m ² (SD)	31.6 (8.1)	Other immunosuppressants	14 (100%)		
	Race and ethnicity		Eculizumab	2 (14%)		
with significant	White, non-Hispanic	11 (79%)	Rituximab	2 (14%)		
disease	White, Hispanic	1 (7%)	Previous intravenous immunoglobin	12 (86%)		
uisease	Asian	2 (14%)	Previous plasma exchange	8 (57%)		
	MGFA class at screening	_(,	Diagnosis of thymoma	0		
		3 (21%)	Previous thymectomy	6 (43%)		
THE LANCET		10 (71%)	Previous myasthenia gravis	4 (29%)		
Nourology	IV	1 (7%)	crisis requiring intubation			
Neurology	Median age of disease onset, years	40 (14-79)	Myasthenia gravis ongoing therapy			
Volume 22, Issue 7, July 2023, Pages 578-590	(range)	40 (14-79)	Pyridostigmine	11 (79%)		
	Median duration of disease, years (range)	14 (3-27)	Prednisone	10 (71%)		
	Myasthenia gravis antibody status		Azathioprine	1 (7%)		
 Baseline MG-ADL mean score of 10 	Anti-AChR antibody	11 (79%)	Mycophenolate mofetil	1 (7%)		
79% were MGFA Class III-IV at	Anti-MuSK antibody	2 (14%)	Mycophenolate moletii	1 (7 76)		
screening	Seronegative (for AChR, MuSK, and LRP4 antibodies)	1 (7%)				
 All patients presented with disease 	Mean baseline scores (SD)					
that was not controlled with	QMG	15.3 (4.1)				
standard of care therapies	MG-ADL	10.0 (3.2)				
	MGC	21.9 (5.7)				
	MG-QoL-15r	19.9 (5.8)				
Cartesian		(/		11		

Descartes-08 was observed to be safe and well-tolerated in MG

THE LANCET
Neurology
Volume 22, Issue 7, July 2023, Pages 578-590

KEY OBSERVATIONS:

- No dose-limiting toxicities
- No cytokine release syndrome
- No neurotoxicity
- No pre-treatment chemotherapy and related cytopenias
- Outpatient treatment

Cartesian

	Grade*	Part 1 (n=3)	Part 2: all groups (n=11)	Part 2: group 1 (n=3)	Part 2: group 2 (n=7)	Part 2: group 3 (n=1)
Hand numbness	2	1 (33%)	0	0	0	0
Headache	1	1 (33%)	5 (45%)	1 (33%)	3 (43%)	1 (100%)
Muscle soreness	1	1 (33%)	1 (9%)	0	1 (14%)	0
Nausea	1	1 (33%)	4 (36%)	2 (67%)	2 (29%)	0
Rash	3	0	1 (9%)	1 (33%)	0	0
Itchy throat	1	0	2 (18%)	0	1 (14%)	1 (100%)
Vomiting	1	0	3 (27%)	2 (67%)	1 (14%)	0
Weakness	1	0	2 (18%)	2 (67%)	0	0
Line infiltration	1	0	1 (9%)	1 (33%)	0	0
Fever	1	0	4 (36%)	1 (33%)	3 (43%)	0
Shortness of breath1	1	0	2 (18%)	1 (33%)	1 (14%)	0
Chills	1	0	2 (18%)	1 (33%)	1 (14%)	0
Diarrhoea	1	0	1 (9%)	1 (33%)	1 (14%)	0
Gum inflammation	1	0	1 (9%)	0	1 (14%)	0
Teeth sensitivity	1	0	1 (9%)	0	1 (14%)	0
Night sweats	1	0	1 (9%)	0	1 (14%)	0
Restless leg	1	0	1 (9%)	0	1 (14%)	0
Light-headedness	1	0	1 (9%)	0	1 (14%)	0


*There were no adverse events of grade 3 or higher reported in part 1, and no grade 2 or grade 4 events reported in part 2, where grade 1 is mild, grade 2 is moderate, grade 3 is severe, and grade 4 is lifethreatening. 'Not associated with hypoxia

12

Descartes-08 observed to induce deep and durable clinical improvement in MG

- Notable magnitude and duration of response across all 4 standard MG severity scales
- Responses appear to deepen after completing treatment at Week 6
- Positive twelve-month follow-up data from Phase 2a study reinforce prior findings published in *Lancet Neurology*

Cartesian




Manuscript submitted for peer review; pre-print available at medRxiv.org


Manuscrip submitted to peer fevine, pre-print available at insurvavioug Efficacy datasets includes all MC patients completing the 6-does one-weekly regimen (n=7). Data are mean score improvement (point) and standard error (light blue shading). Note that QOL scale does not have an agreed-upon threshold for clinically meaningful disease improvement. I/G-ADL, MCC and QMC scales are validated, quantitated, standardized instruments of disease severily and have been acceptable endpoints for registration studies. 13 Descartes-08: Durable depletion of autoantibodies consistent with observed clinical responses and MoA

- All three participants with detectable AChR antibody levels at baseline experienced autoantibody reductions by Month 6
- Reductions deepened further by Month 9, and were maintained at Month 12


Cartesian




Manuscript submitted for peer review; pre-print available at medRxiv.org Anti-acetylcholine receptor, AChR MoA, Mechanism of action 14



Phase 2b randomized, placebo-controlled, double-masked study of Descartes-08 in MG



Exploring potential of Descartes-08 in Systemic Lupus Erythematosus (SLE)



Cartesian

Exploring additional applications for Descartes-08 in autoantibodyassociated autoimmune diseases (AAAD)

 Clinical data suggest that Descartes-08 could lead to clinical benefit along with disappearance of disease-associated autoantibodies, suggesting potential in additional autoimmune indications Potential significant Descartes-08-associated improvement observed in a patient with autoimmune retinitis (AIR)

61-year-old man with DPPX antibody-positive AIR, colitis, encephalitis refractory to prednisone, rituximab, bortezomib, IVIg; positive for 5/5 disease-associated autoantibodies pre-treatment


Post-treatment: experienced a clinically-significant, 2-line improvement in visual acuity; 3 of 5 autoantibodies became undetectable

Test	Pre-treatment	Month 2	Month 4	Month 6
Visual acuity	20/60	20/40	20/40	20/40
Carbonic anhydrase II Ab	+	-	-	NP*
Tubulin Ab	+	-	-	NP*
PKM2 Ab	+	-	-	NP*
Aldolase Ab	+	+	+	NP*
Enolase Ab	+	+	+	NP*

*NP - not performed

Cartesian DPPX, Dipeptidyl-peptidase-like protein 6 IVIg. Intravenous immunoglobulin 18

RNA Armory[®] example: Descartes-15, a next generation anti-BCMA mRNA CAR-T with >10x potency observed in preclinical studies





Cartesian

20

Cite in


cGMP mRNA Synthesis

Clinical grade mRNA production


MSC Cell Banking

Part 1271, FDA-reviewed huMSC collection & banking

 \checkmark



Platform offers potential development opportunities via three modalities: autologous, allogeneic and *in situ*



Maturing pipeline offers potential for multiple catalysts

Descartes-08 in MG		Descartes-08 in SLE					
Expect to report Phase 2b data mid-2024	Mid 2024	Plan to initiate Phase 2 in 1H 2024	1H 2024				
Descartes-08 Additional Indications	_	Descartes-15					
Plan to initiate basket studies in additional autoimmune indications in 2H 2024	2H 2024	IND cleared, with first-in-human Phase 1 planning activities underway	2024				
Funding expected to support development of Descartes-08 through Phase 3 and advance additional programs							
Cartesian			23				

Strong Financial Position Expected to Support Pipeline Through Key Milestones





<60 EMPLOYEES Based in Gaithersburg, MD

*Shares include approximately 166.3 thousand shares of Series A Non-Voting Convertible Preferred Stock that remain subject to beneficial ownership limitations that are convertible into approximately 5.5 million shares of common stock. **Fully diluted shares include diluted shares as described above, as well as outstanding options, RSUs and warrants.

Cartesian

24

17.8M


Basic shares outstanding

23.3M

Basic shares outstanding upon full conversion of outstanding Series A Preferred*

26.6M

Fully diluted shares outstanding**









Differentially expressed B-cell antigens require distinct CAR-T strategies

- CD19+ and CD20+ cells represent the vast majority of B cells and are ubiquitously distributed
- CD19+ and CD20+ are often expressed on the same B cells
- The exceptions are plasma cells, in which neither antigen is expressed, and plasmablasts, in which CD19+ is expressed, directly responsible for pathogenic autoantibodies
- Plasma cells are rare and tissue-restricted






BCMA is a differentiated target with potential for precision CAR-T in patients with autoimmunity

28

Cartesian



<u>Cartesian differentiation</u>: All approved CAR T therapies and other trials in the autoimmune space face fundamental hurdles created by integrating vectors

